Published September 4, 2026
The Justice Department and the Drug Enforcement Administration announced on August 28, 2026 that Walmart agreed to pay $50 million to resolve a federal lawsuit accusing its pharmacies of illegally filling invalid prescriptions for opioids and other controlled substances. The government's complaint, first filed in 2020, alleged Walmart had repeatedly violated the Controlled Substances Act dating back to 2013 by dispensing prescriptions its own pharmacists should have flagged as suspicious.
Beyond the payment, the settlement requires Walmart to strengthen how it screens for potentially unlawful controlled-substance prescriptions, set up a hotline for employees and patients to report suspected illegal dispensing, monitor pharmacy-level dispensing patterns, and build a process for evaluating prescribers suspected of writing unlawful prescriptions. Walmart did not admit liability.
This resolution is separate from — and much smaller than — the roughly $3.1 billion framework Walmart agreed to years earlier to settle opioid claims brought by state and local governments over prescriptions sold at its pharmacies. That earlier settlement addressed civil claims from states and cities; this one resolves the federal government's own regulatory case over Walmart's prescription-filling practices specifically, ending six years of litigation between Walmart and the DOJ.
Neither settlement pays out directly to individuals harmed by opioid use — both are institutional settlements between Walmart and government plaintiffs. People who believe they were harmed by a pharmacy's failure to properly screen opioid prescriptions, or by a manufacturer's role in the broader opioid crisis, pursue that through a separate, individual legal claim.
If you or a family member were harmed by inappropriately dispensed or prescribed opioids, this settlement doesn't affect your ability to pursue your own claim — it's a resolution between Walmart and federal regulators, not a claims fund for individuals. See Atumio's Opioid case page for a free eligibility review, or start your case review directly.